SUZANNE FUQUA to Female
This is a "connection" page, showing publications SUZANNE FUQUA has written about Female.
Connection Strength
0.663
-
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer. Cancer Res. 2026 Apr 02; 86(7):1707-1723.
Score: 0.037
-
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022 02; 126(2):174-186.
Score: 0.027
-
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. Br J Cancer. 2021 01; 124(1):191-206.
Score: 0.025
-
ESR1 mutations in breast cancer. Cancer. 2019 11 01; 125(21):3714-3728.
Score: 0.023
-
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer. Horm Cancer. 2018 08; 9(4):215-228.
Score: 0.021
-
Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol. 2016 12; 31:97-103.
Score: 0.019
-
Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERa-positive breast cancer. Breast Cancer Res Treat. 2015 Nov; 154(2):225-37.
Score: 0.018
-
Role of MTA2 in human cancer. Cancer Metastasis Rev. 2014 Dec; 33(4):921-8.
Score: 0.017
-
Estrogen receptor (ER) a mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat. 2014 Feb; 144(1):11-9.
Score: 0.016
-
Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010 May 15; 16(10):2702-8.
Score: 0.012
-
A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions. Breast Cancer Res Treat. 2010 Jul; 122(2):381-93.
Score: 0.012
-
Pharmacogenetics of breast cancer: toward the individualization of therapy. Cancer Invest. 2009 Aug; 27(7):699-703.
Score: 0.012
-
Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice. Oncogene. 2009 Sep 10; 28(36):3177-87.
Score: 0.011
-
Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol. 2007; 608:130-43.
Score: 0.010
-
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006 Jun 01; 66(11):5950-9.
Score: 0.009
-
Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer. CA Cancer J Clin. 2026 Jan-Feb; 76(1):e70055.
Score: 0.009
-
The c-Yes 3'-UTR contains adenine/uridine-rich elements that bind AUF1 and HuR involved in mRNA decay in breast cancer cells. J Steroid Biochem Mol Biol. 2005 Nov; 97(3):219-29.
Score: 0.009
-
Adipocyte/Tumor cell crosstalk via IGF-1/TXNIP axis promotes malignancy and endocrine resistance in breast cancer. Cell Commun Signal. 2025 Jun 03; 23(1):262.
Score: 0.009
-
The promise of microarrays in the management and treatment of breast cancer. Breast Cancer Res. 2005; 7(3):100-4.
Score: 0.009
-
Genomic approaches in the management and treatment of breast cancer. Br J Cancer. 2005 Feb 28; 92(4):618-24.
Score: 0.008
-
Insights into the role of progesterone receptors in breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):931-2; author reply 932-3.
Score: 0.008
-
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7490-9.
Score: 0.008
-
Evidence that CRISPR-Cas9 Y537S-mutant expressing breast cancer cells activate Yes-associated protein 1 to driving the conversion of normal fibroblasts into cancer-associated fibroblasts. Cell Commun Signal. 2024 Nov 14; 22(1):545.
Score: 0.008
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
Score: 0.008
-
Regulation of the estrogen receptor alpha minimal promoter by Sp1, USF-1 and ERalpha. Breast Cancer Res Treat. 2004 May; 85(2):111-20.
Score: 0.008
-
Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
Score: 0.008
-
Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer. Cancer Res. 2024 01 16; 84(2):291-304.
Score: 0.008
-
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 2024 03; 26(3):266-275.
Score: 0.008
-
Estrogen receptor and breast cancer. Semin Cancer Biol. 2001 Oct; 11(5):339-52.
Score: 0.007
-
The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2001 Oct; 6(4):407-17.
Score: 0.007
-
Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001 Mar; 8(1):47-61.
Score: 0.006
-
Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
Score: 0.006
-
Low cell motility induced by hsp27 overexpression decreases osteolytic bone metastases of human breast cancer cells in vivo. J Bone Miner Res. 1999 Sep; 14(9):1570-5.
Score: 0.006
-
Tumor suppressor genes in breast cancer. Endocr Relat Cancer. 1999 Sep; 6(3):405-19.
Score: 0.006
-
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Ann Oncol. 2019 06 01; 30(6):927-933.
Score: 0.006
-
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9.
Score: 0.006
-
Proteomic profiling identifies key coactivators utilized by mutant ERa proteins as potential new therapeutic targets. Oncogene. 2018 08; 37(33):4581-4598.
Score: 0.005
-
Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Oncogene. 2018 08; 37(33):4489-4504.
Score: 0.005
-
Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines. Cancer Lett. 2018 08 01; 428:12-20.
Score: 0.005
-
Estrogen receptor variants. J Mammary Gland Biol Neoplasia. 1998 Jan; 3(1):73-83.
Score: 0.005
-
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
Score: 0.005
-
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis. Oncogene. 2017 08 10; 36(32):4527-4537.
Score: 0.005
-
An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997 Apr 01; 57(7):1244-9.
Score: 0.005
-
The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis. 1997; 17(3):113-23.
Score: 0.005
-
RNA from air-dried frozen sections for RT-PCR and differential display. Biotechniques. 1996 Sep; 21(3):425-8.
Score: 0.005
-
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 08; 158(3):441-54.
Score: 0.005
-
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
Score: 0.005
-
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat. 2016 06; 157(2):253-265.
Score: 0.005
-
The role of the estrogen receptor in tumor progression. J Steroid Biochem Mol Biol. 1996 Jan; 56(1-6 Spec No):87-91.
Score: 0.004
-
Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat. 1995 Sep; 35(3):233-41.
Score: 0.004
-
Mechanisms of action of antiestrogens. Cancer Treat Rev. 1995 May; 21(3):247-71.
Score: 0.004
-
Targeting thyroid hormone receptor beta in triple-negative breast cancer. Breast Cancer Res Treat. 2015 Apr; 150(3):535-45.
Score: 0.004
-
Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res. 1995 Feb; 1(2):155-9.
Score: 0.004
-
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1688-98.
Score: 0.004
-
AR collaborates with ERa in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014 Oct; 147(3):473-85.
Score: 0.004
-
Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth. Breast Cancer Res Treat. 2014 Jul; 146(2):273-85.
Score: 0.004
-
Prognostic factors and variant estrogen receptor RNAs in clinical breast cancer. Nucl Med Biol. 1994 Apr; 21(3):449-54.
Score: 0.004
-
Estrogen receptor variants in breast cancer. Cancer Treat Res. 1994; 71:97-109.
Score: 0.004
-
An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. Cancer Res. 1993 Dec 15; 53(24):5882-4.
Score: 0.004
-
In vitro mechanism for downregulation of ER-a expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells. Mol Nutr Food Res. 2013 May; 57(5):840-53.
Score: 0.004
-
Expression of estrogen receptor variants. J Cell Biochem Suppl. 1993; 17G:194-7.
Score: 0.004
-
The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat. 1993; 26(2):191-202.
Score: 0.004
-
Novel insights into breast cancer genetic variance through RNA sequencing. Sci Rep. 2013; 3:2256.
Score: 0.004
-
Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Mol Oncol. 2013 Jun; 7(3):379-91.
Score: 0.004
-
Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene. 2013 Jul 04; 32(27):3274-85.
Score: 0.004
-
Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res. 2012 Jun 14; 14(3):R95.
Score: 0.004
-
Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. Breast Cancer Res Treat. 2012 Jul; 134(2):569-81.
Score: 0.004
-
Where is the lesion in hormone-independent breast cancer? J Natl Cancer Inst. 1992 Apr 15; 84(8):554-5.
Score: 0.003
-
Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep. 2012; 2:264.
Score: 0.003
-
Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res. 2012 Mar 15; 72(6):1416-27.
Score: 0.003
-
Abnormal oestrogen receptor in clinical breast cancer. Eur J Cancer. 1992; 28(2-3):309-10.
Score: 0.003
-
Estrogen receptor variants in clinical breast cancer. Mol Endocrinol. 1991 Nov; 5(11):1571-7.
Score: 0.003
-
Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res. 2011 Dec 01; 71(23):7259-69.
Score: 0.003
-
Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res. 2011 Oct 15; 17(20):6510-21.
Score: 0.003
-
Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors. J Natl Cancer Inst. 1991 Aug 21; 83(16):1157-60.
Score: 0.003
-
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27.
Score: 0.003
-
Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 2011 Oct; 25(10):3695-707.
Score: 0.003
-
Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene. 2011 Sep 29; 30(39):4129-40.
Score: 0.003
-
Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52.
Score: 0.003
-
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011 Jan 15; 71(2):603-13.
Score: 0.003
-
Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay. J Natl Cancer Inst. 1990 May 16; 82(10):858-61.
Score: 0.003
-
Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene. 2010 Apr 22; 29(16):2404-14.
Score: 0.003
-
BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol Endocrinol. 2010 Jan; 24(1):76-90.
Score: 0.003
-
Induction of the estrogen-regulated "24K" protein by heat shock. Cancer Res. 1989 Aug 01; 49(15):4126-9.
Score: 0.003
-
Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol. 2009 Sep; 175(3):1270-80.
Score: 0.003
-
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.
Score: 0.003
-
Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res. 2009 Jun 01; 69(11):4724-32.
Score: 0.003
-
Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter. Mol Endocrinol. 2009 Apr; 23(4):454-65.
Score: 0.003
-
P-glycoprotein expression in human breast cancer cells. Cancer Res. 1987 Apr 15; 47(8):2103-6.
Score: 0.002
-
Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin Cancer Res. 2005 Oct 15; 11(20):7579-85.
Score: 0.002
-
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
Score: 0.002
-
Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002. Breast Cancer Res Treat. 2003 Mar; 78(1):127-31.
Score: 0.002
-
Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s.
Score: 0.002
-
Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment. Cancer Lett. 2001 Jan 10; 162(1):3-17.
Score: 0.002
-
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
Score: 0.002
-
Production and characterization of an estrogen receptor beta subtype-specific mouse monoclonal antibody. Hybridoma. 2000 Dec; 19(6):481-7.
Score: 0.002
-
Alterations in the estrogen receptor alpha mRNA in the breast tumors of African American women. J Cancer Res Clin Oncol. 2000 May; 126(5):291-7.
Score: 0.002
-
Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol. 2000 Mar; 14(3):369-81.
Score: 0.002
-
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7.
Score: 0.001
-
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998 May 06; 90(9):697-703.
Score: 0.001
-
Induction of heat shock protein 27 by hydroxyurea and its relationship to experimental metastasis. Clin Exp Metastasis. 1998 Apr; 16(3):283-90.
Score: 0.001
-
MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997 Aug 15; 57(16):3486-93.
Score: 0.001
-
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11.
Score: 0.001
-
p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res. 1994 Jul 15; 54(14):3752-7.
Score: 0.001
-
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74.
Score: 0.001
-
Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol. 1993 Jun; 14(3):173-88.
Score: 0.001
-
Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst. 1993 Apr 07; 85(7):570-4.
Score: 0.001
-
Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat. 1993; 26(3):225-35.
Score: 0.001
-
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26(3):237-46.
Score: 0.001
-
William L. McGuire Memorial Symposium. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat. 1993; 27(1-2):95-102.
Score: 0.001
-
Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res. 1992 Jul 01; 52(13):3648-54.
Score: 0.001
-
Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer. 1991 Jan; 63(1):136-42.
Score: 0.001
-
HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990 Jul 15; 50(14):4332-7.
Score: 0.001
-
Isolation and characterization of an adriamycin-resistant breast tumor cell line. In Vitro Cell Dev Biol. 1990 Jun; 26(6):621-8.
Score: 0.001
-
Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol. 1989 Aug; 7(8):1129-36.
Score: 0.001
-
Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res. 1989 Jan 01; 49(1):145-8.
Score: 0.001
-
P-glycoprotein in breast cancer. Cancer Treat Res. 1989; 48:97-105.
Score: 0.001
-
Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model. Breast Cancer Res Treat. 1988 Jul; 11(3):211-9.
Score: 0.001